Sola Aoun Bahous, M.D. Ph.D.
Sola Aoun Bahous, M.D. Ph.D.
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.
Migraine Headache
Arterial Stiffness
Vitamin K Deficiency
Vitamin K2 or menaquinone-7
Placebo
NA
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 160 participants |
Masking : | QUADRUPLE |
Masking Description : | Patients, investigators, and analysts will remain blind to the identity of the treatment from the time of randomization until the time of unblinding. The identity of the treatment will be concealed by using placebo pills that are identical in appearance, color, odor and packaging. Unblinding will only occur in the case of a medical emergency and at the conclusion of the study. |
Primary Purpose : | TREATMENT |
Official Title : | Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine |
Actual Study Start Date : | 2023-09 |
Estimated Primary Completion Date : | 2024-09 |
Estimated Study Completion Date : | 2024-12 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Lebanese American University Medical Center - Rizk Hospital
Beirut, Lebanon, 11-3288